What is Pulmonary arterial hypertension?
Pulmonary Arterial Hypertension is treated with 19 medications in our database, including Ambrisentan, EPOPROSTENOL, BYQLOVI, Sterile Diluent for Treprostinil, Treprostinil, bosentan, and 14 more. 12 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Gilead, GlaxoSmithKline, Laurus, United Therapeutics, Actelion and others. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Pulmonary Arterial Hypertension treatment below.
Also known as:
- Inheritance
- Variable
- Can be inherited in different ways depending on the underlying gene
- Age of Onset
- Variable
- Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
10 eventsImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. — PHASE1, PHASE2
BOSENTAN: New indication approved
BOSENTAN: New indication approved
Vanderbilt University Medical Center — NA
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.
Treatments
13 FDA-approved · 5 other trackedSource: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
FDA-approved (13)
WINREVAIR
indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC),…
indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death
Flolan
FLOLAN is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity
Sildenafil
indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening
Epoprostenol
indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity
Opsynvi
chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class (FC) II-III)
Tyvaso DPI
Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
Uptravi
Indicated for PAH to delay disease progression and reduce hospitalization risk.
Opsumit
Indicated for PAH to delay disease progression. Dual endothelin receptor antagonist.
Tyvaso
Indicated to improve exercise ability in PAH patients. Prostacyclin analog.
Tadalafil
Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability
Ambrisentan
Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening
Ventavis
Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms
Bosentan
Treatment of pulmonary arterial hypertension.
Other tracked therapies (5)
Medications tracked in our therapeutics database that are not FDA-approved for Pulmonary arterial hypertension via a labelled indication. May include investigational, off-label, or supportive therapies. Always verify with a clinician before use.
BYQLOVI
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Treprostinil, DILUENT
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Revonto
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Oxygen/Nitrogen 38/62
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Sterile Diluent for Treprostinil, Treprostinil
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
Specialty unconfirmed
Gossamer Bio Inc.
Specialty unconfirmed
University of Zurich
Specialty unconfirmed
Brown University
Specialty unconfirmed
Northwell Health
Specialty unconfirmed
University Hospital Zurich, Department of Pulmonology
Specialty unconfirmed
Assiut University
Specialty unconfirmed
UKGM Giessen
Specialty unconfirmed
Department of Thrombosis and Hemostasis LUMC Leiden
Specialty unconfirmed
National Heart Centre Singapore
Specialty unconfirmed
Medical College of Wisconsin
Specialty unconfirmed
Wake Forest University Health Sciences
Specialty unconfirmed
Stanford University
Specialty unconfirmed
Mayo Clinic
Specialty unconfirmed
Chinese Academy of Medical Sciences, Fuwai Hospital
Specialty unconfirmed
Oxford University Hospitals NHS Trust
Specialty unconfirmed
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Specialty unconfirmed
Duke University
Specialty unconfirmed
Marywood University
Specialty unconfirmed
Hospital Clinic of Barcelona
Pulmonology / Pulmonary Vascular Disease
Baylor College of Medicine
Cardiology / Pulmonary Hypertension
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ-UL)
Pulmonology / Pulmonary Hypertension
Tufts Medical Center
Cardiology / Pulmonary Hypertension
George Washington University
Cardiology / Pulmonary Hypertension
The Lundquist Institute at Harbor-UCLA Medical Center
Cardiology / Heart Failure and Pulmonary Hypertension
Weill Cornell Medicine
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Financial Resources
17 resourcesSource: manufacturer patient-assistance programs (PAP) + copay-card programs · NORD Patient Assistance · HealthWell Foundation + disease-specific foundation grants · links verified by automated cron
PAN Foundation — Pulmonary arterial hypertension
PAN Foundation
Pulmonary arterial hypertension
Good Days — Pulmonary arterial hypertension
Good Days
Pulmonary arterial hypertension
NORD Patient Assistance — Pulmonary arterial hypertension
NORD Patient Assistance
Pulmonary arterial hypertension
HealthWell Foundation — Pulmonary arterial hypertension
HealthWell Foundation
Pulmonary arterial hypertension
The Assistance Fund — Pulmonary arterial hypertension
The Assistance Fund
Pulmonary arterial hypertension
Patient Advocate Foundation — Pulmonary arterial hypertension
Patient Advocate Foundation
Pulmonary arterial hypertension
Patient Services Inc — Pulmonary arterial hypertension
Patient Services Inc
Pulmonary arterial hypertension
6 travel grants are also available for Pulmonary arterial hypertension patients — see Travel Grants below ↓
Travel Grants
6 grantsPAN Foundation Pulmonary Hypertension Copay Grant
PAN Foundation
Applicants must be receiving treatment for pulmonary hypertension in the United States and have health insurance that covers their qualifying prescribed medication. Eligibility also requires a household income at or below 500% of the Federal Poverty Level.
Tyvaso Patient Assistance Program
Eligibility generally requires patients to be uninsured or underinsured, reside in the U.S., and demonstrate financial hardship. Specific programs mention income limits up to 500% of the Federal Poverty Level, though many evaluate applications on a case-by-case basis.
GSK for You Patient Assistance Program
GSK
Eligibility is determined by pharmaceutical manufacturers based on income limits, insurance status, and financial need, with specific thresholds like 300% FPL mentioned for certain medications. Programs typically require patients to be either commercially insured for co-pay assistance or uninsured/underinsured for free medication through patient assistance foundations.
Opsumit Patient Assistance Enrollment Form
ONWARD Patient Support Program
UCB
The ONWARD program is available to patients aged 2 years and older who are prescribed FINTEPLA for Dravet syndrome or Lennox-Gastaut syndrome. It provides access to financial support resources, clinical education, and dedicated care coordination to assist with insurance and treatment navigation.
QuickRx Specialty Pharmacy Tyvaso Copay Assistance
QuickRx Specialty Pharmacy
Eligibility is based on having a valid prescription for FDA-approved PAH treatment and varies by insurance type, including commercial, Medicare/Medicaid, or uninsured status. Requirements typically include US residency, age 18 or older, and demonstrated financial need for specific foundation or manufacturer assistance.
Community
No community posts yet. Be the first to share your experience with Pulmonary arterial hypertension.
Start the conversation →Latest news about Pulmonary arterial hypertension
5 articlesSource: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Pulmonary arterial hypertension
What is Pulmonary arterial hypertension?
Pulmonary Arterial Hypertension is treated with 19 medications in our database, including Ambrisentan, EPOPROSTENOL, BYQLOVI, Sterile Diluent for Treprostinil, Treprostinil, bosentan, and 14 more. 12 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Gilead, GlaxoSmithKline, Laurus, United Therapeutics, Actelion and others. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Pulmonary Arterial Hypertension treatment below.
Are there clinical trials for Pulmonary arterial hypertension?
Yes — 14 recruiting clinical trials are currently listed for Pulmonary arterial hypertension on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Pulmonary arterial hypertension?
25 specialists and care centers treating Pulmonary arterial hypertension are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Pulmonary arterial hypertension?
16 FDA-approved treatments and 20 patient support programs are currently tracked on UniteRare for Pulmonary arterial hypertension. See the treatments and support programs sections for copay assistance, eligibility, and contact details.
Frequently asked questions about Pulmonary arterial hypertension
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is Pulmonary arterial hypertension?
Pulmonary arterial hypertension is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:182090). It is typically inherited as variable. Age of onset is generally variable. For verified primary sources, see the UniteRare Pulmonary arterial hypertension page.
How is Pulmonary arterial hypertension inherited?
Pulmonary arterial hypertension follows variable inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for Pulmonary arterial hypertension?
Yes — UniteRare tracks 18 FDA-approved treatments with indications relevant to Pulmonary arterial hypertension. Each entry includes prescribing information, orphan-drug-designation status where applicable, and the FDA application number for verification.
Are there clinical trials recruiting for Pulmonary arterial hypertension?
UniteRare currently lists 14 clinical trials relevant to Pulmonary arterial hypertension sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.
How do I find a specialist for Pulmonary arterial hypertension?
UniteRare lists 25 verified clinicians with documented expertise in Pulmonary arterial hypertension, sourced from ClinicalTrials.gov principal-investigator records, PubMed publication histories, and the NPPES NPI registry. Filter by state or browse our state-specific specialist pages for nearby options.
See full Pulmonary arterial hypertension page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.